What is the value for money of medicines? A registry study

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 182-186

  Simoens, S ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Economic evaluation; Europe; Incremental cost utility ratio; Medicines; Value for money

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CLASSIFICATION; DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; EUROPE; FUNDING; HEALTH CARE UTILIZATION; HUMAN; POLICY; QUALITY ADJUSTED LIFE YEAR; REGISTER; REIMBURSEMENT; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; EUROPE; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; RESEARCH DESIGN;

EID: 84857997270     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01277.x     Document Type: Article

References (15)

1. Grootendorst P, Pierard E, Shim M Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2009;9:353-364.
2. Organisation for Economic Co-operation and Development. (2007) Health at a glance 2007. Paris: Organisation for Economic Co-operation and Development.
3. Crown WH, Ling D, Berndt E Measuring the costs and benefits of pharmaceutical expenditures. Expert Review of Pharmacoeconomics and Outcomes Research, 2002;2:467-475. (Pubitemid 35174806)
4. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Journal of the American Medical Association, 1996;276:1253-1258. (Pubitemid 26337709)
5. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.
6. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
7. Perleth M, Jakubowski E, Busse R What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Policy, 2001;56:235-250. (Pubitemid 32499231)
8. Centre for the Evaluation of Value and Risk in Health. The Tufts Cost-Effectiveness Analysis Registry. Available at: https://research.tufts-nemc. org/cear/default.aspx (accessed 8 March 2010).
9. Brouwer WB, Niessen LW, Postma MJ, Rutten FF Need for differential discounting of costs and health effects in cost effectiveness analyses. British Medical Journal, 2005;331:446-448. (Pubitemid 41176388)
10. Briggs A, Sculpher M, Buxton M Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics, 1994;3:95-104.
11. Cohen JT, Neumann PJ, Weinstein MC Does preventive care save money? Health economics and the presidential candidates. New England Journal of Medicine, 2008;358:661-663. (Pubitemid 351240744)
12. van Gils PF, Tariq L, Verschuuren M, van den Berg M Cost-effectiveness research on preventive interventions: a survey of the publications in 2008. The European Journal of Public Health, 2011;21:260-264.
13. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB Bias in published cost effectiveness studies: systematic review. British Medical Journal, 2006;332:699-703.
14. Drummond M, Brown R, Fendrick AM, Fullerton J, Neumann P Use of pharmacoeconomics information - report of the ISPOR Task Force on use of pharmacoeconomic/ health economic information in health-care decision making. Value in Health, 2003;6:407-416. (Pubitemid 36929727)
15. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs (Millwood), 2000;19:92-109.